Extended Low-Dose Apixaban and Superficial Vein Thrombosis

20261 citationsJournal Articlegreen Open Access

Authors

Sina Rashedi · Brigham and Women's Hospital

Mariana Pfeferman · Brigham and Women's Hospital

Ankur Pandey · Brigham and Women's Hospital

Darsiya Krishnathasan · Brigham and Women's Hospital

Candrika D. Khairani · Brigham and Women's Hospital

Antoine Bejjani · Brigham and Women's Hospital

Ruth Morrison

Abstract

This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism ( HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Blood Coagulation and Thrombosis Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Cardiology

DOI: 10.1001/jamacardio.2026.0151

Field-Weighted Citation Impact: 27.69